Nuance Pharma ("Nuance") announced that the Pharmaceutical Administration Bureau Macau approved Ohtuvayre™ (ensifentrine) for the maintenance treatment of chronic obstructive pulmonary disease (COPD) ...

New classes of drug are based on a better understanding of the complex pathophysiology of asthma and include inhibitors of specific mediators, cytokines and chemokines. Several new classes of drug ...

It is a first-in-class dual inhibitor of PDE3 and PDE4, targeting inflammation and bronchodilation in COPD patients. Moreover, Verona Pharma has partnered with Ritedose for the development and ...

Left ventricular (LV) mass loss is prevalent in doxorubicin (DOX)-induced cardiotoxicity and is responsible for the progressive decline of cardiac function. Comparing with the well-studied role of ...

PDE2 (phosphodiesterase 2) is upregulated in human heart failure. Cardiac PDE2‐transgenic mice are protected against contractile dysfunction and arrhythmias in heart failure but whether an acute ...

Introduction: Cerebral small vessel disease (CSVD) is common among older people and it could lead to dementia. Whether anti-platelet therapy (APT) could retard the cognitive decline of CSVD is unclear ...

It is a first-in-class dual inhibitor of PDE3 and PDE4, targeting inflammation and bronchodilation in COPD patients. Moreover, Verona Pharma (NASDAQ:VRNA) has partnered with Ritedose for the ...

Copyright: © 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.